Who are Bevacizumab + Deferred Aflibercept Group's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bevacizumab-deferred-aflibercept-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bevacizumab + Deferred Aflibercept Group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab + Deferred Aflibercept Group (Bevacizumab + Deferred Aflibercept Group) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic agents; VEGF inhibitors. Area: Oncology.

phase 3 Anti-angiogenic agents; VEGF inhibitors VEGF-A (bevacizumab); VEGF-A, VEGF-B, PlGF (aflibercept) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bevacizumab + Deferred Aflibercept Group (Bevacizumab + Deferred Aflibercept Group) — Jaeb Center for Health Research. This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab + Deferred Aflibercept Group TARGET	Bevacizumab + Deferred Aflibercept Group	Jaeb Center for Health Research	phase 3	Anti-angiogenic agents; VEGF inhibitors	VEGF-A (bevacizumab); VEGF-A, VEGF-B, PlGF (aflibercept)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic agents; VEGF inhibitors class)

Jaeb Center for Health Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab + Deferred Aflibercept Group — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-deferred-aflibercept-group. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab